ArticleBioinformatics and biology insights2025
Integrative Machine Learning Approach to Explore Glycosylation Signatures and Immune Landscape in Moyamoya Disease.
Article in Bioinformatics and biology insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrating machine learning for the identification of ubiquitination-associated genes in moyamoya disease.Frontiers in neurology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Moyamoya disease (MMD) is a rare, chronic cerebrovascular disorder of uncertain etiology. Although abnormal glucose metabolism has been implicated, the contribution of glycosylation-related genes in MMD remains elusive. In this study, we analyzed 2 transcriptome data sets (GSE189993 and GSE131293) from the Gene Expression Omnibus (GEO) database to identify 723 differentially expressed genes (DEGs) between MMD patients and controls. Intersection genes with known glycosylation-related genes underwent Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. We utilized machine learning to select key hub genes, followed by immune cell infiltration and correlation analyses. In-depth immune cell analysis indicated that both CFP and MGAT5B were closely tied to various immune components, suggesting potential crosstalk between glycosylation pathways and immune regulation. Notably, CFP was positively associated with pDCs, HLA, and CCR, whereas MGAT5B correlated with B-cells, check-points, and T helper cells but showed a negative relationship with Tregs, hinting at an immunoregulatory mechanism influencing MMD progression. Motif-TF annotation highlighted csibp_M2095 as the motif with the highest normalized enrichment score (NES: 6.57). Reverse microRNA (miRNA)-gene prediction identified 75 miRNAs regulating these focus genes, along with 126 miRNA-miRNA interconnections. Connectivity Map (Cmap) analysis revealed that Chenodeoxycholic acid, MRS-1220, Phenytoin, and Piceid were strongly negatively correlated with MMD expression profiles, suggesting potential therapeutic candidates. Enzyme-linked immunosorbent assays confirmed elevated CFP and MGAT5B and reduced PTPN11 in MMD, aligning with our bioinformatic findings. Moreover, PTPN11 knockdown in human brain microvascular endothelial cells (HBMECs) significantly enhanced tube formation, indicating a role in vascular remodeling. Collectively, these results emphasize the importance of glycosylation-related genes and immune dysregulation in MMD pathogenesis. These findings broaden our understanding of MMD's underlying mechanisms and underscore the necessity of continued research into glycosylation-driven pathways for improved disease management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.